Overview

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension
Phase:
Phase 2
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited